High response rates after neoadjuvant cytoreductive treatment with BRAF/MEK inhibition of prior unresectable regionally advanced melanoma, REDUCTOR trial. Issue 2 (February 2019) - Blankenstein, S.; Rohaan, M.; Klop, M.; Van der Hiel, B.; Van de Wiel, B.; Peeper, D.; Haanen, J.; van Akkooi, A.